Business Context and Reporting Period
This Form 8-K was filed by Aquinox Pharmaceuticals, Inc. on September 18, 2015. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding the presentation of Phase 2 clinical trial results for bladder pain syndrome/interstitial cystitis (BPS/IC) at the 2015 International Society for the Study of BPS (ESSIC) Conference.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial disclosures and does not contain financial statements or operational financial data.
Material Changes
The material change reported is the public announcement of clinical trial results. The Company presented data from its Phase 2 trial for BPS/IC. The full text of the press release and the accompanying slide presentation are attached as Exhibits 99.1 and 99.2, respectively.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial performance, or specific risk factors beyond the standard legal disclaimer. The information is deemed "furnished" rather than "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, limiting its incorporation by reference in other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific details on the Phase 2 clinical trial outcomes.
- Examine Exhibit 99.2 (Slide Presentation) for the data supporting the clinical results.
- Verify the regulatory status of the BPS/IC treatment candidate following the ESSIC Conference presentation.
- Check subsequent filings for any financial impact or strategic shifts resulting from the trial results.